Cytokinetics, Incorporated CYTK
At closeNov 5, 2026, 4:40 PM EST
After hours · Nov 5, 4:40 PM ET
- YTD
- -12.57%
- 1 year
- -6.15%
- Market cap
- 7.72B
- Revenue (ttm)
- 67.67M
- EPS (ttm)
- -7.22
- Shares out
- 139.02M
- Forward P/E
- -14.45
- YTD return
- -12.57%
- 1-year return
- -6.15%
- Volume
- 6.77M
- Avg volume
- 1.91M
- Open
- 60.04
- Previous close
- 63.60
- Day's range
- 54.16 – 60.84
- 52-week range
- 54.16 – 88.31
- Beta
- 0.47
- Analysts
- Strong Buy
- Price target
- 107.39 (+93.3%)
- Earnings date
- Feb 23, 2027
5D -8.39 (-13.12%)
Key statistics
- Enterprise value
- 8.92B
- PEG ratio
- 0.00
- Price / sales
- 130.66
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -57.10%
- Free cash flow
- -397.41M
- Total cash
- 1.17B
- Total debt
- 1.42B
- Return on equity
- 0.00%
- Short % of float
- 20.46%
- 50-day average
- 66.91
- 200-day average
- 70.07
Analyst view
Consensus: strong buy
- Target (low)
- 81.00
- Target (mean)
- 107.39
- Target (high)
- 140.00
- Strong buy7
- Buy13
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate -1.41.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | -1.43 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -1.43 | -1.37 | +0.06 | +4.20% |
| Aug 6, 2026 | Jun 30, 2026 | -1.63 | -1.50 | +0.13 | +7.98% |
| May 5, 2026 | Mar 31, 2026 | -1.67 | -1.67 | 0.00 | 0.00% |
| Feb 24, 2026 | Dec 31, 2025 | -1.48 | -1.50 | -0.02 | -1.35% |
| Nov 5, 2025 | Sep 30, 2025 | -1.59 | -2.55 | -0.96 | -60.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Oct 8, 2026 | RBC Capital | main | Outperform | Outperform |
| Aug 31, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2026 | Barclays | main | Overweight | Overweight |
| Aug 13, 2026 | JP Morgan | main | Overweight | Overweight |
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cytokinetics.com
News
Citigroup Maintains Buy on Cytokinetics, Raises Price Target to $105 
Leerink Partners Maintains Outperform on Cytokinetics, Lowers Price Target to $100 
Cytokinetics, Incorporated (CYTK) Q3 2026 Earnings Call Transcript 
Cytokinetics Q3 Earnings Call Highlights 
Cytokinetics (CYTK) Reports Q3 Loss, Beats Revenue Estimates 
Cytokinetics Q3 2026 Earnings Call Transcript 
Cytokinetics Q3 EPS $(1.37) Beats $(1.44) Estimate, Sales $47.557M Beat $41.879M Estimate 
Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update 
Cytokinetics to Participate in November Investor Conferences 
Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
Your note
Sign in to keep a note on CYTK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BHANJI MUNA | Director | Stock Award(Grant) | May 26, 2026 | 26,361 |
| BLUM ROBERT I | Chief Executive Officer | Sale | Nov 1, 2026 | 282,710 |
| CALLOS ANDREW | Officer | Sale | Aug 30, 2026 | 58,555 |
| HARRINGTON ROBERT ARTHUR | Director | Stock Award(Grant) | Oct 15, 2026 | 22,127 |
| HENDERSON JOHN TANNAHILL | Director | Stock Award(Grant) | Oct 15, 2026 | 78,795 |
| HESSEKIEL JEFFREY J | Officer | Stock Award(Grant) | Mar 12, 2026 | 107,943 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.15% | 20,094,362 | 1.28B | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 15.04% | 18,718,498 | 1.19B | Jun 29, 2026 |
| Wellington Management Group, LLP | 5.57% | 6,931,770 | 440.86M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.39% | 6,711,799 | 426.87M | Jun 29, 2026 |
| State Street Corporation | 5.22% | 6,494,233 | 413.03M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.92% | 6,117,515 | 389.07M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 5.05% | 6,285,983 | 399.79M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.98% | 4,952,045 | 314.95M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.47% | 4,314,356 | 274.39M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.81% | 3,491,654 | 222.07M | Sep 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.69% | 3,341,262 | 212.50M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.50% | 3,114,802 | 198.10M | Jun 29, 2026 |